A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Summary
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
Eligibility
- Age range
- 22+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant must have histologically or cytologically confirmed metastatic colorectal adenocarcinoma. There must be previous documentation of RAS (Rat sarcoma mutation), BRAF (B-Raf proto-oncogene, Serine/threonine kinase), MSI/MMR (microsatellite instability, mismatch repair) , and HER2 (Human epidermal growth factor receptor 2) status. * Participant must have progressed on or been intolerant to the following previous treatments (if not contraindicated): * Fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy * Anti-VEGF (vascular endothelial growth fac…
Interventions
- DrugFruquintinib
Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class
- DeviceTheraBionic P1
TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device
Locations (9)
- Karmanos Cancer Institute at McLaren Bay RegionBay City, Michigan
- Karmanos Cancer Institute at McLaren ClarkstonClarkston, Michigan
- Karmanos Cancer InstituteDetroit, Michigan
- Karmanos Cancer Institute at McLaren FlintFlint, Michigan
- Karmanos Cancer Institute at McLaren Greater LansingLansing, Michigan
- Karmanos Cancer Institute at McLaren Lapeer RegionLapeer, Michigan